AbClon Inc. (KOSDAQ:174900)

South Korea · Delayed Price · Currency is KRW

24,600

-950 (-3.72%)

Oct 12, 2026, 3:30 PM KST

Market Cap	490.82B +41.6%
Revenue (ttm)	5.31B +75.0%
Net Income	-17.73B
EPS	-907.64
Shares Out	19.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	168,710
Open	25,450
Previous Close	25,550
Day's Range	24,600 - 26,700
52-Week Range	16,250 - 95,800
Beta	0.77
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About AbClon

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company’s products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2010

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 174900

Full Company Profile

Financial Performance

In 2025, AbClon's revenue was 4.71 billion, an increase of 101.47% compared to the previous year's 2.34 billion. Losses were -18.10 billion, 11.1% more than in 2024.

Financial Statements